Japanese medical equipment maker Terumo has established a $75 million corporate venture capital fund aimed at investing in advanced technologies for cardiovascular treatment. This initiative, launched through its Terumo Ventures division, reflects the company’s strategic focus on potential mergers and acquisitions to drive future growth.
The new venture arm will operate from Terumo’s Americas Holding unit, with additional bases in Boston, Silicon Valley, and Belgium. The fund will target startups specializing in cardiovascular and chronic disease treatments, as well as digital health technologies. Terumo plans to invest in approximately 25 companies over the next five years.
Terumo has been actively engaged in the U.S. venture capital scene since 2013, evaluating over 2,000 startups. In China, the company has been investing in startups through venture capital since 2020. By leveraging these experiences, Terumo aims to incorporate cutting-edge technologies to enhance its product offerings and maintain its competitive edge in the medical equipment industry.
This strategic expansion into venture capital underscores Terumo’s commitment to innovation and its goal of integrating new technologies to address the growing challenges in cardiovascular and chronic disease treatment.
